Trial · NCT01839084

PaNeX: Partial Nephrectomy Under Xenon

NCT01839084, Phase 3, Completed, RWTH Aachen University

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. PaNeX: Partial Nephrectomy Under Xenon. Trials, record NCT01839084. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01839084

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: PaNeX: Partial Nephrectomy Under Xenon
NCT number: NCT01839084
Status: Completed
Phases: Phase 3
Enrollment: 46 participants, actual
Lead sponsor: RWTH Aachen University
Conditions: Renal Function After Partial Nephrectomy
Interventions: Xenon, Isoflurane
First posted: 2013-04-24
Last updated: 2016-02-18
Other registries' IDs: eudract:2012-005698-30

Source ClinicalTrials.gov

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Evaluation of the impact of xenon-anesthesia on the renal function after partial nephrectomy, compared to an isoflurane-anesthesia.	Within the first 7 postoperative days	Evaluation of the maximum decrease of glomerular filtration rate (GFR) within 7 days after partial nephrectomy surgery. Maximum decrease will be assessed by the difference between the baseline value of GFR and the minimum value of GFR after surgery.
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	Intraoperatively	Ischaemia time
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	Intraoperatively	Duration of xenon/isoflurane exposition before and after the kidney ischemia time.
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	Intraoperatively until discharge from hospital	Tumor size and histology, if applicable detection of hypoxia-inducible factor 1α (HIF-1α) in healthy resection border tissue
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	Intraoperatively and within the first 7 postoperative days	Measurement of macrophage migration inhibitory factor (MIF) in serum
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	preaoperativ and Within the first 7 postoperative days	Course of GFR determined with the Cystatin C value in serum
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	preaoperativ and Within the first 7 postoperative days	Course of creatinine value in serum
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	Within the first 7 postoperative days	Urine output within the first 48houres after surgery
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	Within the first 7 postoperative days	If applicable determination of kidney injury molecule-1 (KIM-1)or neutrophil gelatinase-associated lipocalin (NGAL)
Secondary	Secondary efficacy criteria for using xenon-anaesthesia during partial nephrectomy.	Within the first 7 postoperative days	Determination of acute kidney failure according to the AKIN classification

1 to 10 of 15Source ClinicalTrials.gov

See all 15 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
28719609	DERIVED	PubMed
31288740	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01839084

GET https://conductscience.org/api/trials/v1/NCT01839084/registered

API reference For AI assistants